Fasenra 30 mg Pen: Uses, Safety and Storage
Quick summary Fasenra® 30 mg solution for injection in a pre-filled pen contains benralizumab. It is used for certain eosinophilic asthma and eosinophilic granulomatosis cases, and it is given by subcutaneous injection. Medical disclaimer...
This content is for educational purposes only and does not replace medical advice, diagnosis or treatment from a qualified healthcare professional.
Quick summary
Fasenra® 30 mg solution for injection in a pre-filled pen contains benralizumab. It is used for certain eosinophilic asthma and eosinophilic granulomatosis cases, and it is given by subcutaneous injection.
Medical disclaimer
This article is for general information only and does not replace the official patient leaflet, prescribing information, or advice from a doctor or pharmacist. It does not provide personal diagnosis or treatment guidance.
What is Fasenra® 30 mg solution for injection?
Fasenra® is a medicine containing the active ingredient benralizumab. It is given as a subcutaneous injection and is available in a pre-filled pen.
The original content describes it as an important treatment option for eosinophilic asthma and eosinophilic granulomatosis. It is designed to help reduce eosinophil levels in the body.
How does Fasenra® work?
Fasenra® targets the IL-5 receptor on eosinophils. According to the source content, this helps reduce eosinophil numbers and their lifespan.
In simple terms, the intended effect is to lower eosinophil-driven inflammation, which may help improve respiratory symptoms in the conditions described above.
Key points from the mechanism
- Targeted action: It binds to the IL-5 receptor.
- Eosinophil depletion: It helps reduce eosinophil levels.
- Inflammation reduction: Lower eosinophils may mean less airway inflammation.
How is Fasenra® given?
Fasenra® is administered by subcutaneous injection. The original content states that it is typically given every 4 to 8 weeks, depending on the patient’s condition and the healthcare provider’s instructions.
The injection can be given in the thigh, abdomen, or upper arm. If a pre-filled pen is used, it is designed to make administration easier.
Fasenra® pre-filled pen: what to know
The pre-filled pen is presented as a convenient option for self-administration. The original content notes that it may be easier to use than a syringe for some patients.
Both the pen and syringe forms contain the same active ingredient, but the device choice may depend on patient preference and the healthcare professional’s recommendation.
Common side effects
The original content lists the following common side effects:
- Headache
- Sore throat
- Injection site reactions such as redness or swelling
- Fatigue
These effects are described as usually mild to moderate. If symptoms persist, worsen, or feel unusual, a doctor or pharmacist should be contacted.
Serious reactions and when to seek help
The source content also mentions that serious allergic reactions can occur in rare cases. Warning signs may include difficulty breathing, swelling of the face or throat, or a rash.
If any severe reaction is suspected, urgent medical help is needed.
Warnings and precautions
Before treatment, the original content says patients should discuss the following with their healthcare provider:
- Allergies: especially any history of allergic reactions.
- Infections: monitoring for signs of infection during treatment.
- Vaccinations: checking whether any vaccines need special consideration.
- Other medicines: sharing a full medication list to help avoid problems.
For the most accurate advice, the official leaflet and prescribing information should always be checked.
How to store Fasenra®
The original content gives the following storage instructions:
- Store in a refrigerator at 2°C to 8°C (36°F to 46°F).
- Keep it protected from light.
- Do not freeze it.
- After removal from the refrigerator, it can be kept at room temperature for up to 14 days.
Proper storage helps maintain the medicine’s quality and safety.
Cost and access
The cost of Fasenra® can vary depending on insurance coverage, location, and the pharmacy or healthcare setting. The original content also notes that patient assistance programs may be available in some cases.
For practical cost questions, a pharmacist, clinic, or insurer can usually provide the most relevant information.
Frequently asked questions
▸ What is Fasenra 30 mg used for?
The original content says it is used for eosinophilic asthma and eosinophilic granulomatosis. It works by reducing eosinophils, which are involved in inflammation.
▸ What is the difference between the pen and the syringe?
Both contain the same active ingredient. The pre-filled pen is designed to be easier for self-administration, while the syringe may suit different preferences or clinical instructions.
▸ Is Fasenra a chemotherapy drug?
No. The original content describes Fasenra® as a targeted biologic therapy, not chemotherapy.
▸ Where is Fasenra injected?
It is given by subcutaneous injection, typically in the thigh, abdomen, or upper arm, according to the original content.
▸ What side effects are mentioned in the source content?
Headache, sore throat, injection site reactions, and fatigue are listed as common side effects. Serious allergic reactions are also mentioned as rare but important to watch for.
Safety reminder
Always follow the instructions provided by your healthcare professional and check the official leaflet for the most up-to-date information on use, storage, and safety. If you notice severe symptoms or a possible allergic reaction, seek urgent medical help.
Sources to verify
For the most reliable details, readers should verify information in official product documents and trusted medical references.
| Source type | What to check |
|---|---|
| Official patient leaflet | Uses, administration, storage, and warnings |
| Prescribing information | Approved indications and safety details |
| Pharmacist or clinician | Practical use, storage, and device questions |
Medical disclaimer
This content is for educational purposes only. It should not be used as a substitute for professional medical advice, diagnosis or treatment. Always ask a doctor, pharmacist or qualified healthcare professional before starting, stopping or changing any medicine.
Sources and verification
The following sources or official references are listed to support verification of the medicine information discussed in this article.
- Official Fasenra patient leaflet
- Fasenra prescribing information
- European Medicines Agency product information
To improve this article with specific references, add a custom field named _aio_sources in the post editor and write one source per line using: Source title|Source URL.
Medicine information can change and may vary depending on country, product formulation, patient history and professional guidance. Always check official medicine information and ask a healthcare professional for personal medical questions.